CD4 and cancer: RK treatment ameliorated cancer‐induced T‐lymphopenia (TCR‐β+: −27.5 ± 12.8%; CD4+: −20.8 ± 13.8%; and CD8+: −31.4 ± 12.9%; P > 0.05) (Figure7D–F).